Terminal
Intelligence

Hourly Briefing ·

Infiniti Intelligence Hourly Briefing — Oct 31, 2026 · 8:15 AM ET

1 story in this edition: Chances of Retatrutide winning FDA approval this year rise slightly to 8.7 percent

Chances of Retatrutide winning FDA approval this year rise slightly to 8.7 percent

Polymarket traders raised the chance that the FDA approves Retatrutide this year to 8.7 percent, up 3.8 points in 24 hours. The market has 597,000 dollars in lifetime volume and resolves on January 1, 2027.

Approval odds rise but remain low

Polymarket’s probability of FDA approval for Retatrutide this year reached 8.7 percent, increasing 3.8 points over 24 hours, according to PredictionBubbles.

The update, published Oct 31, 2026, at 8:15 AM ET, shows traders assigning a higher likelihood to approval before year-end. Even after the increase, the market continues to put that outcome at a low probability.

Trading volume and resolution

The market has recorded 597,000 dollars in lifetime trading volume, according to PredictionBubbles. That figure covers activity over the market’s lifetime, rather than just the 24 hours in which the probability rose.

The contract resolves on January 1, 2027. The supplied report does not identify a regulatory development or other catalyst behind the move, so the repricing alone does not establish that the FDA’s position has changed.

What it means for prediction markets

  • A higher probability, not a likely outcome: The 3.8-point increase brought approval odds to 8.7 percent, leaving approval this year a low-probability result in market pricing.
  • Volume has a different timeframe: The 597,000 dollars represents lifetime turnover and does not show how much trading accompanied the latest move.
  • Timing matters: The question concerns approval this year, with resolution on January 1, 2027; it does not measure the likelihood of eventual approval.

Sources & attribution

Published
  1. Source
    PredictionBubblespredictionbubbles.com
    Publisher
    https://predictionbubbles.com
    Source URL
    The feed did not publish this story's article address.

Full attribution under the Digital Millennium Copyright Act (DMCA), 17 U.S.C. § 512: this article is an original report by Infiniti Intelligence that summarizes the reporting of the publishers named above, links to their original work, and reproduces no protected expression beyond brief factual reference and in-line attribution (“according to PredictionBubbles”). All rights in the underlying reporting remain with the publishers listed; nothing here implies endorsement by or affiliation with them. Rights holders may request correction, update or removal through the contact address published at infiniti.w3ai.io.